VetStem v. Rocky Mountain Regenerative Medicine: Stem Cell Therapy Patents Settle
VetStem, Inc. asserted two patents covering regenerative stem cell therapies against Colorado-based Rocky Mountain Regenerative Medicine. The case resolved via a consummated settlement after 244 days, with all claims and counterclaims dismissed with prejudice and each party bearing its own costs.
Stem Cell IP Dispute Reaches Negotiated End in Colorado
VetStem, Inc., a veterinary regenerative medicine company and holder of US9453202B2 and US11129855B2, filed a patent infringement action against Rocky Mountain Regenerative Medicine Prof., LLC in the Colorado District Court on March 8, 2024. Both patents relate to regenerative stem cell therapies, a commercially active and scientifically evolving field. The filing targeted a Colorado-based professional LLC offering competing regenerative medicine services.
The case closed on November 7, 2024, after the parties notified the court of a consummated final settlement agreement. All claims brought by VetStem against RMRM and all counterclaims brought by RMRM against VetStem were dismissed with prejudice by joint stipulation. Critically, the parties agreed that each would bear its own costs and attorney’s fees, a term that typically signals a negotiated compromise rather than a clear-cut win for either side.
The 244-day resolution is notably swift for patent litigation, suggesting the parties may have reached common ground before extensive discovery or claim construction proceedings. The public record does not disclose the financial or licensing terms underlying the settlement, leaving open whether VetStem secured ongoing royalties, a license, or a covenant not to sue. The dismissal with prejudice forecloses any re-filing of the same claims, providing RMRM with finality on the asserted patents.
Filing to Dismissed with Prejudice in 244 days
244 days from filing to closure — faster than the median patent case lifespan in U.S. district courts.
Case settled with prejudice: what the resolution means for both parties
Dismissed with prejudice via joint stipulation
A dismissal with prejudice following a settlement means the claims are permanently extinguished — VetStem cannot re-file the same infringement allegations against RMRM on these patents for the same conduct. The joint stipulation signals mutual agreement rather than a court-imposed outcome, and the underlying settlement terms remain confidential absent further disclosure.
Permanent bar on re-filingVetStem exits with confidential terms and finality
VetStem achieved closure without trial risk, preserving the validity of both asserted patents on the public record — neither was invalidated by court judgment. The consummated settlement suggests VetStem may have secured licensing or behavioural commitments from RMRM, though these are not disclosed. Bearing its own costs is consistent with a negotiated compromise.
Patents remain unchallengedRMRM gains finality; counterclaims also extinguished
Rocky Mountain Regenerative Medicine secured dismissal of all VetStem claims and successfully had its own counterclaims resolved in the same settlement. The own-costs arrangement avoids a fee-shifting award. RMRM avoids any court finding of infringement or damages, though the dismissal with prejudice means it cannot revive its counterclaims if the settlement breaks down.
No infringement finding on recordStem cell therapy IP remains live enforcement risk
The settlement preserves VetStem’s patents in force with no validity ruling, meaning US9453202B2 and US11129855B2 continue to represent enforcement risk for other regenerative medicine providers operating in overlapping technology spaces. Competitors and new entrants in veterinary or human stem cell therapy should treat these patents as active FTO considerations.
Patents enforceable post-settlementFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Vetstem, Inc. | Company | Veterinary regenerative medicine company — holder of US9453202B2 and US11129855B2Search in Eureka ↗ |
| Defendant | Rocky Mountain Regenerative Medicine Prof., LLC | Company | Colorado-based professional LLC offering regenerative medicine services.Search in Eureka ↗ |
| Plaintiff counsel | Glenn Schuyler Orman | Attorney | Counsel for Vetstem, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jonathan Tad Suder | Attorney | Counsel for Vetstem, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard Allen Wojcio , Jr. | Attorney | Counsel for Vetstem, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Friedman Suder & Cooke PC | Law Firm | Representing Vetstem, Inc.Search in Eureka ↗ |
| Defendant counsel | Carolyn Valerie Juarez | Attorney | Counsel for Rocky Mountain Regenerative Medicine Prof., LLCSearch in Eureka ↗ |
| Defendant counsel | Erin Anne Kelly | Attorney | Counsel for Rocky Mountain Regenerative Medicine Prof., LLCSearch in Eureka ↗ |
| Defendant law firm | Bryan Cave Leighton Paisner LLP | Law Firm | Representing Rocky Mountain Regenerative Medicine Prof., LLCSearch in Eureka ↗ |
| Defendant law firm | Neugeboren O’Dowd P.C. | Law Firm | Representing Rocky Mountain Regenerative Medicine Prof., LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Colorado District CourtSearch in Eureka ↗ |
Official order — verbatim text
The joint notice confirms a fully consummated settlement — not merely an agreement in principle — providing strong procedural finality. The with-prejudice dismissal of both claims and counterclaims extinguishes all asserted causes of action permanently. The own-costs term is noteworthy: absent a fee-shifting agreement, neither party admits liability or concedes the strength of the other’s position, which is consistent with a commercially negotiated resolution rather than a capitulation by either side.
US9453202B2 & US11129855B2 — Regenerative Stem Cell Therapy Technologies
US9453202B2 and US11129855B2 relate to regenerative stem cell therapies — a technology domain encompassing the isolation, preparation, and therapeutic application of stem cells for tissue repair and regenerative treatment. US9453202B2 issued from application US10/575063, reflecting earlier priority, while US11129855B2 issued from the more recent US16/859790, suggesting an extended prosecution strategy designed to maintain coverage as the field matured. Together, these patents suggest a layered portfolio approach to protecting core regenerative medicine methods.
For competitors and new entrants in regenerative medicine — whether in veterinary applications, human therapeutics, or adjacent cell therapy platforms — VetStem’s patent portfolio represents a live enforcement risk. The settlement in this case did not produce any invalidity ruling or claim construction, meaning the full scope of these patents remains untested. Companies developing or commercialising stem cell therapies should conduct FTO analysis against both patents before launching products or expanding services into markets where VetStem operates.
Should you run an FTO against US9453202B2 and US11129855B2?
Any organisation developing, licensing, or commercialising regenerative stem cell therapies — including veterinary clinics, human cell therapy developers, and contract research organisations — should assess freedom to operate against VetStem’s patent portfolio. The absence of a court invalidity ruling means both patents stand at full force. Given VetStem’s demonstrated willingness to litigate, proactive FTO review is commercially prudent before product launch or service expansion.
PatSnap Eureka’s FTO Search Agent can map your specific product or process against the claim scope of US9453202B2 and US11129855B2, identify relevant prior art that could support a challenge, and flag prosecution history estoppel that may limit claim breadth. Eureka’s landscape view also surfaces related VetStem filings and competitor patents in the regenerative medicine space, giving IP teams a comprehensive risk picture before making commercialisation decisions.
Run a freedom-to-operate analysis on US9453202B2 to assess your product’s exposure
Run FTO in Eureka →Similar Stem Cell & Regenerative Medicine Patent Cases
Cases involving regenerative stem cell therapy patents litigated in U.S. district courts, with comparable infringement claims and settlement or dismissal outcomes.
What this case signals for the regenerative medicine IP landscape
A swift settlement with prejudice in a stem cell therapy dispute carries distinct signals for IP strategy in the regenerative medicine sector.
Rapid settlements preserve patent enforceability for future actions
Because no court ruled on validity or infringement, VetStem’s two stem cell therapy patents emerge from this litigation untested and fully enforceable. Patent holders in the regenerative medicine space who settle early retain maximum optionality for future enforcement against other parties.
Own-costs terms signal neither party held strong litigation leverage
Fee-neutral settlements typically indicate that neither party was confident enough in its position to demand cost-shifting. For defendants facing stem cell IP assertions, early negotiation before substantive motions practice can limit exposure and avoid the risk of an exceptional-case finding under 35 U.S.C. § 285.
Vetstem v Rocky — key questions answered
VetStem asserted two patents: US9453202B2 (application US10/575063) and US11129855B2 (application US16/859790), both covering regenerative stem cell therapy technologies. The case was filed in the Colorado District Court on March 8, 2024.
The case settled after 244 days. The parties notified the court of a consummated final settlement agreement, and all claims and counterclaims were dismissed with prejudice by joint stipulation. Each party agreed to bear its own costs and attorney’s fees. Settlement financial terms are not publicly disclosed.
Dismissal with prejudice means VetStem cannot re-file the same infringement claims against RMRM for the same conduct. However, the patents themselves were not invalidated by any court ruling — they remain fully enforceable against other parties in the market. The settlement preserves VetStem’s enforcement options outside this specific dispute.
Yes. The joint settlement notice references counterclaims brought by RMRM against VetStem, which were also dismissed with prejudice as part of the settlement. The nature of those counterclaims — potentially invalidity or non-infringement — is not detailed in the public record.
Because the case settled without a court ruling on validity or claim scope, US9453202B2 and US11129855B2 remain in force at full strength. Regenerative medicine companies, veterinary practices, and cell therapy developers operating in overlapping technology areas should treat both patents as live FTO risks and consider conducting freedom-to-operate analysis before commercialising relevant products or services.
PatSnap Eureka searches patents and litigation data to answer instantly.